Baseline characteristics expressed as frequencies and percentages if not otherwise stated
| bioSAVR n=9539 | |
| Age at index intervention median (Q1–Q3) | 73 (67–78) |
| Sex | |
| Female | 3509 (36.8%) |
| Male | 6030 (63.2%) |
| LVEF | |
| >0.50 | 6991 (73.1%) |
| 0.30–0.50 | 2072 (21.7%) |
| <0.30 | 496 (5.2%) |
| Coronary intervention at index intervention* | 3285 (34.4%) |
| Medical history | |
| Diabetes | 1833 (19.2%) |
| Hypertension | 3736 (39.2%) |
| Ischaemic stroke | 819 (8.6%) |
| Systemic embolism | 314 (3.3%) |
| Pulmonary embolism and venous thromboembolism | 684 (7.2%) |
| Haemorrhagic stroke | 36 (0.4%) |
| Other bleeding event | 355 (3.7%) |
| Myocardial infarction | 1264 (13.3%) |
| Peripheral artery disease | 612 (6.4%) |
| Heart failure | 1234 (12.9%) |
| Atrial fibrillation | 1454 (15.2%) |
| Previous thoracic surgery | 470 (4.9%) |
| Previous percutaneous coronary intervention | 1105 (11.6%) |
*Coronary intervention at index intervention; coronary artery bypass grafting or percutaneous coronary intervention within 3 months.
bioSAVR, surgical aortic valve replacement with a biological prosthesis; LVEF, left ventricular ejection fraction at index intervention.